Arming T cells with activating FcγRIIIa receptors for antibody redirected lysis of cancer cells

      Background: Adoptive T cell therapy (ACT) has proven to be efficient against hematologic malignancies. As ACT is mostly based on artificial receptors recognizing single antigens expressed on cancer cells, major limitations include antigen-loss of tumor cells as well as side effects. Designing T cells with variable antigen targeting limited in time would have considerable advantages both in terms of safety and efficacy. In order to create such a flexible but efficient system, we armed T cells with fusion receptors consisting of the extracellular portion of an antibody-binding-receptor (Fcγ receptor IIIA, synonymous CD16) and the intracellular domains of CD28 and CD3z. Combining this platform with different clinically approved monospecific antibodies could provide a versatile treatment strategy. Variation of the specificity of the antibody and the receptor affinity for its Fc part could potentially enhance efficacy and safety of either therapy alone.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect